Navigation Links
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
Date:10/31/2007

Small molecule drug inhibits key DNA repair mechanism involved in

resistance

DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced during an oral presentation at the American Society for Therapeutic Radiology and Oncology's (ASTRO) 49th Annual Meeting in Los Angeles that MP470, its clinical-stage multi-targeted tyrosine kinase inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract No. 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented here suggests that MP470 inhibits DNA damage repair through suppression of a critical DNA repair protein, Rad51. Dr. James Welsh of the University of Arizona, who conducted these pre-clinical studies, also revealed that the pre-clinical activity of MP470 against glioblastoma multiforme cells is synergistic with radiation.

Glioblastoma multiforme is often resistant to cytotoxic therapies and radiation, due to increased DNA repair and the inhibition of programmed cell death. Signaling pathways downstream of tyrosine kinases such as PDGFR and c- Met, are thought to be a key player in this resistance. Scientists at SuperGen found that MP470 inhibits these kinases and data presented today indicate that MP470 is active in inducing cell death in glioblastoma multiforme cell lines. Additionally, data suggest that MP470 induces sensitization to radiation through suppression of Rad51, indicating that it might not only inhibit tumor growth, but that it could also potentially enhance
'/>"/>

SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Indian American Scientist at Work on Multi-targeted Drug
2. Phase 3 trials of two multi-kinase inhibitors against cancer
3. Enzyme Urokinase Better Option In Empyema For Kids
4. Blood pressure control with ACE inhibitor or diuretic?
5. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
6. Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression
7. Rejuvenation of Stem cells by GSK-3 Inhibitor
8. COX-2 inhibitors Lessen Breast Cancer Risk
9. LipB Protein Inhibitors Help To Fight Against TB
10. Birth Defects Link With ACE Inhibitor Use, FDA Reports
11. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...has got the approval of US Food and Drug Administr...ation (ANDA) for Meloxicam tablets used in the tre... // The approval is for Meloxicam tablets of stre... the company informed the Bombay Stock Exchange. "...
... injection users in US and South Africa practice u...g to a new study. // "Forty percent of the HIV-pos...risk male partners, and more than half of the time... said lead author Dr. Mary H. Latka. The study is ...
...children are to be weighed, measured and interview...ned to tackle //the growing menace of childhood ob...about 25 percent of the children aged between 7 an... This problem is increasing the incidence of heart...
...ation confirmed the 42nd human bird flu death in I... the two worst-hit by the virus,//a senior officia...day. "The result was positive, we received from t... today," Hariadi Wibisono, the director at the min...
Other Medicine News:
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...T WORTH, Texas, Aug. 26 /- Healthpoin... trial to evaluate the effectiveness of a,widely p...aneous wounds and,resulting scars. The pilot study... reduced incidence of hypertrophic scars and benef...se SANTYL(R) Ointment.(1,2), "Given the findings ...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
(Date:8/26/2008)...TTLE, Aug. 26 /- Omeros Corporation t... a Phase 1/Phase 2 trial investigating,OMS103HP in...onstruction,surgery. OMS103HP is an investigationa...ation solution and is designed to improve postoper...ve pain and allow patients an,earlier return to wo...
Breaking Medicine Technology:Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2New technology enhances therapeutic potential of cord blood stem cells 3551 1New technology enhances therapeutic potential of cord blood stem cells 3551 2DURECT Corporation to Participate in Upcoming Healthcare Conferences 5853 1Walking Golf Course Affects Swing Performance 21249 1Walking Golf Course Affects Swing Performance 21249 2US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 1US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 2US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 3US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 4US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 5
...he Intramuscular Formulation,of Peramivir Supports...za, BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-Fi...ed results from two Phase I,clinical studies of an...the Options for the Control of Influenza Conferenc...ional influenza,conference is held only once every...
...PRNewswire-FirstCall/ --,Genaera Corporation today...quemine (MSI-1436), its novel anti-obesity compoun...67th Scientific,Sessions, June 22 to 25 in Chicago...ine is a Multiple,Pathway Inhibitor that Causes Di...roves Plasma Insulin and Leptin Levels." , The pos...
Other Medicine Technology:BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 2Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 3Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 4
IOL choppers for positioning intraocular lenses. Blunt tip avoids damage to intraocular lenses. Formed 10mm from tip. For .20mm diameter holes and larger.
J Cortex Extrator - Angled Right
Cortex Extractor - Charleux
Bimanual Aspiration Cannula
Medicine Products: